Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 121 of the 128 references it cites were found in a registry or an index; 143 of the 228 sources its claims cite were checked for support.
Abstract
Review of major molecular alterations in pancreatic cancer.
Overview
CoChat Summary
TL;DR
This is a narrative review of the roles of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer, emphasizing how their alterations shape tumor biology, prognosis and potential targeted treatment strategies. It argues that molecular profiling can support risk assessment, early detection and more personalized therapy, but also shows that many of these biomarkers still need further validation.
Key findings
- TP53 mutations are reported in 50–90% of pancreatic ductal adenocarcinomas and in 60–70% of cases in another section; they are linked to carcinogenesis, chemotherapy resistance and prognosis. TP53 mutations were also reported across pancreatic lesions, from 9.1% of intermediate-grade IPMNs to 75% of invasive ductal adenocarcinomas.
- CDKN2A alterations are described as common and clinically relevant: somatic mutations are reported in up to 95% of pancreatic tumors, and in TCGA analysis patients with CDKN2A mutations or deep deletions had poorer overall survival and primary therapy outcomes. The paper also states that CDKN2A-inactivated PDAC showed increased sensitivity to paclitaxel and SN-38.
- SMAD4/DPC4 loss is repeatedly associated with worse outcomes and metastasis. In one PDAC cohort of 249 patients, 43% lacked SMAD4 expression and 45% were positive; intact SMAD4 expression was associated with median survival of 19.2 months versus 14.7 months without SMAD4. In another cohort of 348 PDAC patients, 53% had DPC4/Smad4 expression loss.
- KRAS is the most frequently mutated gene in pancreatic cancer, reported at 90–95% in pancreatic adenocarcinomas and near 100% in PDAC in one section. The review also notes studies where KRAS mutations were found in 74.7% of EUS-FNA samples and 62.6% of ctDNA samples, and that ctDNA KRAS mutations were associated with shorter median survival.
Methods
- Narrative review of published studies on the molecular biology, prognosis and therapeutic targeting of TP53, CDKN2A, SMAD4 and KRAS in pancreatic cancer.
- The paper synthesizes findings from human cohorts, TCGA/bioinformatics analyses, liquid biopsy studies, and preclinical mouse/cell line experiments.
- Main analysis is qualitative integration of reported mutation frequencies, survival associations, and treatment-response observations across the cited literature.
Limitations
- The paper does not describe a systematic review protocol, search strategy, inclusion criteria, or meta-analysis; this is evident from the text.
- The review itself notes that the prognostic impact of some markers remains unsettled, e.g. CDKN2A mutations are “still being investigated” and the impact on treatment response “requires further exploration.”
- It also states that SMAD4 effects on chemotherapy response may vary by treatment regimen and disease stage, indicating incomplete or context-dependent evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Modifiable factors include smoking, alcohol, obesity and dietary factors, where red meat increases risk, while vegetables and fruits offer protection. Non-modifiable risk factors comprise gender, age (with increased risk after 50), ethnicity, diabetes, family history, genetic factors, chronic infections and ABO blood group (non-O associated with higher risk). Created with BioRender.com (accessed on 27 February 2024) [13].](https://figures.cochat.ai/paper-figures/1e688da2d762458a9850f21c4797fbbf/significance-of-tp53-cdkn2a-smad4-and-kras-in-pancreatic-cancer-figure-1.jpg)


Verification
Claims the paper makes
106 Valid · 3 Not valid · 52 Not checked · 2 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This multifunctional protein also facilitates the activation of receptor-regulated SMADs (R-SMADs), including SMAD3 and SMAD1, highlighting its role in orchestrating downstream events [62,81].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 4. SMAD4 > 4.1. TGF-β Signaling and Tumor Suppression/Promotion
What the sources say
- Supportedcites [62] Liu L. Li Q. Yang L. Li Q. Du X. SMAD4 Feedback Activates the Canonical TGF-β Family Signaling Pathways Int. J. Mol. Sci. 2021 22 10024 10.3390/ijms221810024 34576190 PMC8471547 source
The Discussion states that SMAD4 induced R-SMAD activity by increasing phosphorylation in porcine granulosa cells, naming p-SMAD3 and p-SMAD1. It qualifies the evidence: p-SMAD3 was reported in a previous study, while the p-SMAD1 result was from ongoing research with data not shown. (LLM, conf=0.88)
- Disputedcites [81] Zhao M. Mishra L. Deng C.X. The role of TGF-β/SMAD4 signaling in cancer Int. J. Biol. Sci. 2018 14 111 123 10.7150/ijbs.23230 29483830 PMC5821033 sourceExperimental — accuracy not yet measured
In “The role of SMAD4 in TGF-β signaling pathway” (page not provided), the paper identifies SMAD1 and SMAD3 as R-SMADs but describes their activation in the opposite order from the claim: the receptor phosphorylates SMAD2/3 before they form a complex with SMAD4. It describes SMAD4 as a mediator of downstream signaling, not as facilitating R-SMAD activation. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The TP53 mutational status-based genomic signature emerges as a critical factor for disease prognosis and therapeutic responses.”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang F. Zhong W. Li H. Huang K. Yu M. Liu Y. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer Front. Cell Dev. Biol. 2021 9 665265 10.3389/fcell.2021.665265 34124046 PMC8187932 source
The Discussion states that the TP53-associated signature can stratify prognosis and serve as a therapeutic indicator in pancreatic cancer. The Results also say it might guide selection of chemotherapeutic agents, supporting the claim about therapeutic responses in that disease. (LLM, conf=0.91)
- Not checked yetcites [22] Liu Y. Cheng L. Song X. Li C. Zhang J. Wang L. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer Math. Biosci. Eng. 2022 19 191 208 10.3934/mbe.2022010 34902987 source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [23] Liu X. Chen B. Chen J. Sun S. A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer BMC Cancer 2021 21 335 10.1186/s12885-021-08066-2 33789615 PMC8011162 sourceExperimental — accuracy not yet measured
The Results report that TP53-mutated patients had significantly worse overall survival in three pancreatic cancer cohorts, and the Discussion describes a seven-gene TP53-related signature for prognosis prediction. The cited passages do not establish that the signature predicts therapeutic responses. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genetic analysis indicates complex interactions among KRAS, CDKN2A, TP53 and SMAD4 alterations, influencing metastatic burden and survival [26].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [26] Yachida S. White C.M. Naito Y. Zhong Y. Brosnan J.A. Macgregor-Das A.M. Morgan R.A. Saunders T. Laheru D.A. Herman J.M. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors Clin. Cancer Res. 2012 18 6339 6347 10.1158/1078-0432.CCR-12-1215 22991414 PMC3500447 source
The Results section (page unavailable in our copy) describes patterns of coexisting KRAS, CDKN2A, TP53 and SMAD4 alterations. It reports that the number of altered driver genes was significantly correlated with metastatic burden, disease-free survival and overall survival. The claim is supported as an association; the study does not establish causation. (LLM, conf=0.91)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Pancreatic cancer commonly features mutations in key genes, such as KRAS, p16/CDKN2A, TP53 and SMAD4/DPC4 [3,4,5] (Table 1).”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [3] Maitra A. Hruban R.H. Pancreatic cancer Annu. Rev. Pathol. 2008 3 157 188 10.1146/annurev.pathmechdis.3.121806.154305 18039136 PMC2666336 source
- Supportedcites [4] Saiki Y. Jiang C. Ohmuraya M. Furukawa T. Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models Cancers 2021 14 71 10.3390/cancers14010071 35008235 PMC8750056 source
The Introduction identifies KRAS, CDKN2A, TP53 and SMAD4 as the four main genetic drivers of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Sections 2.1, 2.4 and 2.5 further describe alterations in KRAS, SMAD4 and CDKN2A; section 2.5 identifies p16 as a CDKN2A product. (LLM, conf=0.91)
- Supportedcites [5] Hu H.-F. Ye Z. Qin Y. Xu X.-W. Yu X.-J. Zhuo Q.-F. Ji S.-R. Mutations in key driver genes of pancreatic cancer: Molecularly targeted therapies and other clinical implications Acta Pharmacol. Sin. 2021 42 1725 1741 10.1038/s41401-020-00584-2 33574569 PMC8563973 source
The Introduction names KRAS, CDKN2A, TP53, and SMAD4/DPC4 as the main driver genes in pancreatic cancer. Figure 1 identifies KRAS, CDKN2A, TP53, and SMAD4 as the most commonly mutated genes in the TCGA pancreatic-cancer dataset. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The accuracy of this genomic signature is underscored by its association with the immunophenotype of PDAC [21,22,23].”
§ Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer > 2. TP53 > 2.2. TP53 Mutations and Poor Prognosis
What the sources say
- Supportedcites [21] Zhang F. Zhong W. Li H. Huang K. Yu M. Liu Y. TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer Front. Cell Dev. Biol. 2021 9 665265 10.3389/fcell.2021.665265 34124046 PMC8187932 source
The Discussion reports that the TP53-associated signature was an accurate, independently validated prognostic predictor and could reflect immune cell infiltration. The Results section on immune cell infiltration reports correlations between signature risk scores and specific immune-cell populations in pancreatic cancer. Together, these support the claimed association with immunophenotype, though the paper does not use the exact phrase ‘underscored by.’ No page numbers are available in our copy. (LLM, conf=0.88)
- Not checked yetcites [22] Liu Y. Cheng L. Song X. Li C. Zhang J. Wang L. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer Math. Biosci. Eng. 2022 19 191 208 10.3934/mbe.2022010 34902987 source
Checked before — its earlier verdict is held back until a new check runs.
- Supportedcites [23] Liu X. Chen B. Chen J. Sun S. A novel tp53-associated nomogram to predict the overall survival in patients with pancreatic cancer BMC Cancer 2021 21 335 10.1186/s12885-021-08066-2 33789615 PMC8011162 source
The Results section, “Immune cell infiltration analysis and GSEA” (page unavailable), reports significant differences in immune-cell fractions between the signature’s high- and low-risk groups. The paper also reports prognostic performance for the signature; describing the immune association as underscoring its accuracy is the citing authors’ interpretation. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
66 more claims · 39 with their cited sources checked
Create a free account to see all 163 claims and to verify the 24 references still open.
- It may state two separate claims as one. 88
- Borderline: one of the tests for a substantial claim is unclear. 1
- Probably not a substantial claim. 4
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 1×
“A copy number analysis revealed recurrent gains and losses, implicating genes like MET and CDKN2A [87].”
BackgroundExosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · cited 1×
“Exosomes expressing CD47 demonstrated enhanced circulation and accumulation in pancreatic tumors, effectively reducing KrasG12D mRNA levels and inhibiting tumor growth in mouse models [96].”
BackgroundEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Epidemiology of pancreatic cancer
Ilic, M., & Ilic, I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i44.9694 · Cited by 1,301
Bloomston, M., Frankel, W. L., Petrocca, F., Volinia, S., Alder, H., Hagan, J. P., Liu, C.-G., Bhatt, D., Taccioli, C., & Croce, C. M. (2007) · JAMA · doi:10.1001/jama.297.17.1901 · Cited by 1,141
Phenotype and Genotype of Pancreatic Cancer Cell Lines
Deer, E. L., González-Hernández, J., Coursen, J. D., Shea, J. E., Ngatia, J., Scaife, C. L., Firpo, M. A., & Mulvihill, S. J. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c15963 · Cited by 936 · cited 1×
“Discrepancies in the mutational status of TP53 and CDKN2A/p16 among cell lines caution researchers about discrepancies between laboratory-specific and literature-reported mutational statuses [20].”
BackgroundKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Research works printed but not linked: 2
- CDKN2A Cyclin Dependent Kinase Inhibitor 2A [Homo Sapiens (Human)] 2024 Available online: https://www.ncbi.nlm.nih.gov/gene/1029 (accessed on 26 December 2023)
- Lovely B. Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer Oncol. Live 2023 24 12 Available online: https://www.onclive.com/view/explorations-unearth-new-potential-of-kras-mutations-in-pancreatic-cancer (accessed on 3 December 2023)
Cited by
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy
Yu, B., Shao, S., & Ma, W. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217350 · Cited by 132
Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities
Lin, Z., Adeniran, E. A., Cai, Y., Qureshi, T. A., Li, D., Gong, J., Li, J., Pandol, S. J., & Jiang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13071733 · Cited by 47
Liu, R., Li, J., Liu, L., Wang, W., & Jia, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.07.004 · Cited by 39
Dahiya, D. S., Malik, S., Paladiya, R. D., Ahsan, S., Waseem, H., Bharadwaj, H. R., Goel, A., Jaan, A., Hayat, U., Hasan, F., et al. (2025) · Cancers · doi:10.3390/cancers17071085 · Cited by 23
Graham, S., Dmitrieva, M., Costa, D. B. V., Francescone, R., Trujillo, M. A. M., Cukierman, E., & Wood, L. D. (2024) · Carcinogenesis · doi:10.1093/carcin/bgae064 · Cited by 19
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery
Wang, C., & Lu, X. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.09.005 · Cited by 14
Verloy, R., Privat‐Maldonado, A., Audenaerde, J. R. M. V., Rovers, S., Zaryouh, H., Waele, J. D., Quatannens, D., Peeters, D. J. E., Roeyen, G., Deben, C., et al. (2025) · Cells · doi:10.3390/cells14060450 · Cited by 12
Shenoy, A., Yousif, A., & Hussain, M. D. (2025) · Cancers · doi:10.3390/cancers17081319 · Cited by 14
Advancing pancreatic cancer management: the role of artificial intelligence in diagnosis and therapy
Ozsahin, D. U., Usanase, N., & Özşahin, İ. (2025) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-025-00610-4 · Cited by 12
Revolutionizing pancreatic cancer treatment with CAR-T therapy
Baghel, K., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.008 · Cited by 9
Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions
Bendari, A., Vele, O. E., Baskovich, B. W., Bendari, A., Sebika, M., Marti, J. L. G., Krishnamurthy, K., & Asiry, S. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16040039 · Cited by 8
Emerging biomarkers for pancreatic cancer: from early detection to personalized therapy
Jamal, M. H., Porel, P., & Aran, K. R. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-03947-5 · Cited by 15
The role of HSPB1 in modulating ferroptosis in pancreatic cancer via the TP53/SLC7A11/GPX4 axis
Tian, Z., Liu, Q., Luo, J., Ning, N., & Qu, J. T. (2025) · Discover Oncology · doi:10.1007/s12672-025-02803-w · Cited by 7
Predictive biomarkers of pancreatic cancer metastasis: A comprehensive review
Chen, M., Liu, H., Xiao, Y., Liang, R., Xu, H., Hong, B., & Qian, Y. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120176 · Cited by 8
Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection
Azim, M. M. N., Bhajan, S. K., Park, J. H., Abass, K. S., Rahman, A., Choi, M., Choi, J., Park, S., Kim, H. J., Akter, S., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072954 · Cited by 8
Suhail, M., Tabrez, S. S. M., Tarique, M., Muhammad, N., Rehan, M., Zughaibi, T. A., & Alhashmi, M. H. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152353 · Cited by 9
Salihoğlu, R., Nieves, J., Dandekar, G., Ebert, R., Rudert, M., Dandekar, T., & Bencúrová, E. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.09.028 · Cited by 6
Advances in the application of extracellular vesicles in precise diagnosis of pancreatic cancer
Yu, H., Xin, C., Zhou, Y., & Ding, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02739-5 · Cited by 6
Safa, A., Vruzhaj, I., Gambirasi, M., & Toffoli, G. (2025) · Cancers · doi:10.3390/cancers17213506 · Cited by 7
Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions
Nagaraju, G. P., Nellipudi, H. R., Ganji, C., Kuppala, V., Ganji, S. P., Kumari, S., Farran, B., Srilatha, M., Guenter, R. E., & El‐Rayes, B. F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02705-5 · Cited by 9
Michetti, F., Cirone, M., Strippoli, R., D’Orazi, G., & Cordani, M. (2025) · Discover Oncology · doi:10.1007/s12672-025-02400-x · Cited by 10
Boudreault, J., Rahimirad, S., Wang, N., Yan, G., Lima, L. C., Poulet, S., Dai, M., Ali, S., & Lebrun, J. J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02587-9 · Cited by 5
Lee, M., Ham, H., Lee, J., Lee, E. S., Chung, C. H., Kong, D.-H., Park, J.-R., & Lee, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111420 · Cited by 6
Brandeburg, Z. C., Adio, W. S., Derewonko, C. A., Dunn, C. E., Pfeiffer, E. C., Flusche, A. M., Sheaff, R. J., & Lamar, A. A. (2024) · ChemMedChem · doi:10.1002/cmdc.202400536 · Cited by 4
DNA Damage and Repair in Pancreatic Cancer—The Latest Findings
Kozłowska, M., Mik, M., Nowicki, M. O., & Śliwińska, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010106 · Cited by 5
Polysaccharides as therapeutic vehicles in pancreatic cancer
Kumari, S., Peela, S., Nagaraju, G. P., & Srilatha, M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104320 · Cited by 5
Sharma, R., Kumar, S., Komal, K., Ghosh, R., Thakur, S., Pal, R. R., & Kumar, M. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04094-y · Cited by 6
TGF-β–YY1 signaling as a key driver of immune evasion in pancreatic cancer: Therapeutic implications
Ho, M. P., Jung, M., Ung, W., Skouradaki, E., Baritaki, S., & Bonavida, B. (2026) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2026.01.005 · Cited by 6
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma
Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 7
Vitamin D and Pancreatic Ductal Adenocarcinoma—A Review of a Complicated Relationship
Grosu, I., Constantinescu, A., Baltă, M. D., Bajenaru, O. A., Nuță, C. R., Pavel, C. J. V., Şandru, V., Munteanu, M. A., & Andronic, O. (2024) · Nutrients · doi:10.3390/nu16234085 · Cited by 4
Lipolysis gone rogue: the HSL connection in feeding cancer
Hemadri, K., Subramanian, P., Aravindan, S., Periyasamy, L., & Aravindan, N. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10098-4 · Cited by 5
A multi-objective artificial bee colony approach for identifying cancer driver pathways
Rodríguez-Bejarano, F. M., Vega-Rodríguez, M. A., & Santander‐Jiménez, S. (2025) · Expert Systems with Applications · doi:10.1016/j.eswa.2025.127071 · Cited by 3
Berloco, F., Zaccaria, G. M., Altini, N., Colucci, S., & Bevilacqua, V. (2025) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2025.102526 · Cited by 5
Pancreatic Cancer and Diabetes: Insights, Hypotheses, and Next Steps
Hill, J. L. E., Hill, T. G., Parslow, D. S., & Hill, D. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110245 · Cited by 6
Hálková, T., Bunganič, B., Traboulsi, E., Minárik, M., Zavoral, M., & Benešová, L. (2024) · Genes · doi:10.3390/genes15101302 · Cited by 5
Sunildutt, N., Ahmed, F., Salih, A. R. C., Kim, H. C., & Choi, K. H. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109481 · Cited by 4
Piano, M. A., Boldrin, E., Moserle, L., Salerno, N., Fanelli, D., Peserico, G., Biasin, M. R., Magni, G., Varano, V., Zalgelli, G., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011090 · Cited by 3
Emerging therapeutic advancements in pancreatic cancer: a contemporary review
Malla, M., Sakr, Y., Gupta, G., Akce, M., & El‐Rayes, B. F. (2025) · Discover Oncology · doi:10.1007/s12672-025-03027-8 · Cited by 8
Behery, F. A., Gendy, M. A. M. E., Zarka, M. A., Alzubaidi, M. A., Abou‐Zied, H. A., Bringmann, G., Abdelmohsen, U. R., & Elmaidomy, A. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-03891-y · Cited by 3
Mughal, N. A., Mahmud, O., Rompen, I. F., Riachi, M. E., Kaplan, B. J., Hewitt, D. B., Sacks, G. D., Wolfgang, C. L., & Javed, A. A. (2025) · HPB · doi:10.1016/j.hpb.2025.12.026 · Cited by 2
Unraveling the therapeutic landscape of miRNAs in pancreatic cancer
El‐Moaty, Z. A., Wasef, M. W., Elsayed, Y. A., Shafiq, A. S., Elnagar, M. A., Mohamed, H. R., Elesawyf, A. E., Mageed, S. S. A., Mohammed, O. A., Abdel‐Reheim, M. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04301-w · Cited by 2
Moyana, T. N., & Merz, V. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1651566 · Cited by 3
Catching pancreatic cancer early: Are we there yet?
Rasheed, A. R. A., Koh, R. Y., Lim, W.-M., Mai, C., & Looi, C.-K. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.12.001 · Cited by 5
Ras Homolog Family Member V Promotes Pancreatic Ductal Adenocarcinoma Progression
Wu, S., Feng, J., Wang, T., Hwa, K., Kao, S., Xiao, Y., Yang, D., Li, X., Li, Z., Liu, R., et al. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.02.002 · Cited by 1
Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer
Yadav, B., Kollur, S. P., Ali, A., Arora, P., Gupta, A., Saranraj, P., Upadhye, V. J., & Singh, P. (2026) · Discover Oncology · doi:10.1007/s12672-026-05130-w · Cited by 1
Witz, A., Conroy, T., Lambert, A., Salleron, J., Diallo, A., Husson, M., Nicolle, R., Hammel, P. R., Biagi, J., Renouf, D. J., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02508 · Cited by 2
Immordino, B., Rocco, M. A., Comandatore, A., van der Zee, G., Vahabi, M., Morelli, L., & Giovannetti, E. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101408 · Cited by 1
Takrori, E., Abdulmajid, M., Devagudi, D., Sohail, R., Sadiq, Z., Berneau, C., Shenouda, A., Adelli, R., Peshin, S., & Singal, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104413 · Cited by 3
Single-Cell Genomics and Somatic Variation in Circulating and Cardiac Resident Cells
Hilal, N., Arava, M., & Choudhury, S. (2026) · Circulation Research · doi:10.1161/circresaha.125.325797 · Cited by 3
Ghosh, D., Kazi, A., Vasiyani, H. K. K., Vudatha, V., Lecomte, N., Iacobuzio–Donahue, C. A., Trevino, J., & Sebti, S. M. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116255 · Cited by 2
Ali, S. M., Adnan, Y., Ahmad, Z., Chawla, T. U., & Ali, S. A. (2024) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2416888 · Cited by 1
Xie, F., Ren, Y.-Z., Jian, Z., Peng, J.-Y., Jiang, H., Lu, Y.-M., Zhang, C., Li, Z., Zhang, Q., Cui, J.-J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.039 · Cited by 3
Witt, R. C., Dunn, C. E., Zanders, L. A., Edema, A. A., Adio, W. S., Derewonko, C. A., Franzen, L. C., Osborn, P. L., Caudle, J. D., Sheaff, R. J., et al. (2025) · ChemMedChem · doi:10.1002/cmdc.202500136 · Cited by 1
Brügel, M., RIVIERE, V., Hubert, A., Langanay, L., Bouché, O., Génin, M., GAUTHIER, V., & Oudart, J. (2026) · Pancreatology · doi:10.1016/j.pan.2026.03.002 · Cited by 1
Kanhailal, A. C., Knikman, J. E., Zielhuis, S. W. J., Kodach, L. L., Bernards, R., Huitema, A. D. R., Tibben, M. M., Voest, E. E., Gerrits, B. M., Siebinga, H., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116782 · Cited by 4
Pancreatic cancer and its association with abdominal pain
Tarasiuk, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41638-5.00011-9
Varzaru, B., Croitoru, A. E., Sorop, A., Lupescu, I. G., Dima, S., Iacob, R. A., Becheanu, G., & Gheorghe, C. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9030285
Wang, J., Xu, K., Xu, L., Geng, J., Liu, C., Gu, X., & Li, X. (2026) · Cancer Management and Research · doi:10.2147/cmar.s573143 · Cited by 1
Carbohydrate antigen 19-9: a key biomarker in cancer diagnosis and therapeutics
Ashwani, Bhamboo, N., Bharadwaj, A., & Gugulothu, D. B. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44041-0.00023-4 · Cited by 1
Fiorino, S., Hong, W., de Biase, D., Mastrangelo, L., Maccioni, F., Grottesi, A., Ambrosi, F., Pincigher, L., Lari, F., Bergamini, C., et al. (2026) · Cancers · doi:10.3390/cancers18121932
Theranostics in pancreatic cancer
Singh, R. K., Yadav, A. K., Dada, R., Tiwari, P., Kumar, A., Yadav, A., Gowerdhan, S. A., Paul, G., Pandey, S. K., Singh, S., et al. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34199-1.00005-3
Manjunath, G. K., Kanchi, L. P., Dakal, T. C., Beura, A., & Kumar, A. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01921-0
Genetic instability profile in individuals exposed to low doses of ionizing radiation: A pilot study
Mikhaleva, M., Yudina, V., Ivanova, K. A., Bakay, M. P., Zherniakova, A., Степановна, М. И., Крысюк, О. Б., & Бессмельцев, С. С. (2026) · Extreme Medicine · doi:10.47183/mes.2026-513
Risikofaktoren und molekulare Evolution des Pankreaskarzinoms
Yavas, A., Vesce, R., Sabo, S. M., & Esposito, I. (2026) · Die Onkologie · doi:10.1007/s00761-026-01999-y
Massaro, G., Lavacchi, D., Innocenti, T., Polvani, S., Galli, A., Taddei, A., Petroni, G., Rossini, D., Pillozzi, S., & Antonuzzo, L. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.09.002 · Cited by 2
Innovative Approaches in Pancreatic Cancer Treatment
Arora, A., Ghosh, B., Khanra, P. K., Choudhury, S., & Ghosh, S. S. (2026) · Springer eBooks · doi:10.1007/978-981-95-6845-1_14
Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges
Habib, R., Arnold, E., Obi, T., Vizeacoumar, F. J., & Ahmed, S. (2026) · Current Oncology · doi:10.3390/curroncol33080452 · Cited by 1
Robic, V., Collin, M., Dupont, J., Jardali, G., Choucair, A., Dawi, L., Lawrance, L., Goldschmidt, V., Massard, C., Smolenschi, C., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116768
Kan, M. U., & Ayan, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177610
Nakka, N. M. R., Rachamala, H. K., Madamsetty, V. S., Angom, R. S., Dutta, S. K., Wang, E., Bhattacharya, S., Pal, K., & Mukhopadhyay, D. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102181
Argyris, P. P., & Herzberg, M. C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00134-0
Николаевич, Т. К., Biryukova, Y. K., Kapranov, V. A., Сергеевна, Н. А., Orlova, E. A., Kozhemyakin, G. L., Demyashkin, G. A., Gordeychuk, I. V., Ishmukhametov, A. A., & Kolyasnikova, N. M. (2026) · Biomedicines · doi:10.3390/biomedicines14081763
Wang, Y., Geng, J., Gong, J., Li, Y., Liu, X., Sheng, W., & Zhen, Y. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107188
Hiyama, K., Nishigawa, M., Takagi, K., Sato, K., Hara, R. I., Furihata, K., Uchida, K., Wada, T., & Taniuchi, K. (2026) · Human Cell · doi:10.1007/s13577-026-01458-1
Bhattacharya, S., Saha, I., Mukherjee, S., Rachamalla, H. K., Gaiani, L., Albelal, D., Angom, R. S., Wang, E., Dutta, S., Dutta, N., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218651
Chakraborty, A., Anirudh, Guillén, P., Le, T. D. V., & Menon, G. P. (2026) · Advanced Gut & Microbiome Research · doi:10.1155/agm3/2541702
Targeting KRAS for cancer therapy
Jia, J., Liu, R., Adamide, T. A., Fernandez, I. E., & Stathopoulos, G. T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70546 · Cited by 4
Mata, R., Alberti, P., García-Illescas, D., Aguilar, S., Castet, F., Fabregat-Franco, C., Vega, S., Masachs, M., Abu–Suboh, M., Blanco, L., et al. (2026) · Endoscopic Ultrasound · doi:10.1097/eus.0000000000000197
Advances in Biomarkers for Pancreatic Cancer
Zou, Y., Li, Y., & Zou, C. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.135019
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
Choo, S., Chae, K., Lee, J., Kim, I., & Lee, S. S. (2026) · Medicinal Research Reviews · doi:10.1002/med.70105
Deng, E., Mareboina, M., Georgakopoulos‐Soares, I., & Yee, N. S. (2026) · Biomedicines · doi:10.3390/biomedicines14050992
Xavier, C. B., Shah, P. A., Yakimova, D., Kravets, A., Belousov, D. M., Kudryavtseva, K., Massaro, M., Paradiso, F., Kotlov, N., Zhao, D., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0344 · Cited by 2
Precision Treatment: The Promise of Targeted Therapies Against Pancreatic Cancer
Singh, S., Kumar, P., Kumar, D., & Mishra, A. K. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-1469-3.ch010
Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma
Igarashi, Y., Shirai, Y., Honma, S., Yamahata, Y., Akaoka, M., Tanji, Y., Taniai, T., Yanagaki, M., Haruki, K., Furukawa, K., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20340-w
Chanda, H. M. K. C., & Katari, S. K. (2026) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2026.109504
Strategy for early diagnosis of pancreatic cancer
Sharma, R. K., Singh, A., Sharma, G., Dawra, S., & Rana, S. S. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1731223
Anticancer potential of berberine: Molecular pathways and current clinical trial perspectives
Maaz, M., Sultan, M. T., Israr, M., Khan, W. A., Tanveer, F., Hussain, M., Imran, M., Mujtaba, A., Memon, A. G., Atif, M., et al. (2026) · JSFA reports · doi:10.1002/jsf2.70079
Genetics of Pancreatic Cystic Tumors
Sharma, R. K., Singh, A., Rana, S. S., & Mishra, N. K. (2026) · Springer eBooks · doi:10.1007/978-981-92-0654-4_13
Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma
Roy, I., & Thakur, R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04289-6 · Cited by 1
Fang, Y., Xu, Y., Xing, F., Zhang, W., Liang, C., Meng, Q., Li, J., Xu, J., Wang, W., Qin, Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1660313 · Cited by 2
Zhao, A., Tu, D., He, Y., Liu, L., Wu, B., & Ren, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1497254 · Cited by 1
Biomarkers for Malignant and Nonmalignant Diseases of the Pancreas
Downie, J. M., Mills, K. C., Majumder, S., & Hernandez-Barco, Y. G. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.10.005
Cross-Disciplinary Mechanistic Insights in Molecular Medicine
Kuo, C.-Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb48010019
Rodríguez-Bejarano, F. M., Santander‐Jiménez, S., & Vega-Rodríguez, M. A. (2026) · Information Sciences · doi:10.1016/j.ins.2026.123182
Ai, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.gu20451
Wu, J., Chen, J., Elkihel, A., Lan, W., Fraunhoffer, N. A., Zhu, D., Lian, B., Galanakou, C., Bian, Z., Liu, X., et al. (2026) · Advanced Science · doi:10.1002/advs.76840
Mericoz, C. A., Kulaç, İ., Alper, E., Adsay, V. N., & Firat, P. (2025) · Acta Cytologica · doi:10.1159/000549794
Metadata
- Authors
- Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- First Department of Surgery, Laikon General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
- University of California, Los Angeles (US)
- Corresponding author
- Toutouzas, Konstantinos G.
- ORCID
- Venue
- Current Issues in Molecular Biology
- Publisher
- MDPI AG
- Published
- 2024-03-23
- Volume
- 46
- Issue
- 4
- Pages
- 2827-2844
- ISSN
- 1467-3037 (ISSN-L)
- 1467-3045
- PMC
- PMC11049225
- OpenAlex
- W4393164529
- Cited by
- 110
- References
- 128
- Citations by year
- 2026: 55 · 2025: 42 · 2024: 13
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Issues in Molecular Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic cancer, TP53, CDKN2A, SMAD4, KRAS, tumor suppressor, p53 deficiency, prognostic value, targeted therapy, molecular signatures, cancer risk assessment, early detection, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.